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discharge, there was a signiﬁcant difference found between the
two groups for three muscle tests; chest press (p.023), leg
extension (p.007) and the isometric right knee ﬂexor test
(p.033). Though signiﬁcant values were not reached on all
tests, the differences between the pre- and post-scores of the
two groups for all physical capacity tests are between 16% and
35%, suggesting that the intervention was efﬁcient in prevent-
ing loss of and maintaining physical capacity.
Findings revealed that exercising patients during hospitalization
for allo-HSCT was feasible, safe and effective. In conclusion,
preventative and anticipatory interventions can minimize physical
and functional loss during hospitalization for allo-HSCT.
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CO-STIMULATORY MOLECULE EXPRESSION BY TRANSPLANTED DO-
NOR APC AND HOST CD4 T CELLS IS REQUIRED TO ELICIT RESISTANCE
AGAINST MHC-MATCHED HEMATOPOIETIC ALLOGRAFTS FOLLOWING
REDUCED INTENSITY CONDITIONING
Jones, M.1, Blazar, B.P.2, Zimmerman, Z.1, Levy, R.B.1 1University of
Miami Miller School of Medicine, Miami, FL; 2University of Minne-
sota, Minneapolis, MN.
Circumventing host resistance to hematopoietic progenitor
cell grafts is crucial for successful engraftment and the induc-
tion/maintenance of immune tolerance. We are studying the
regulation of pathways that lead to T cell resistance in recipients
transplanted with MHC-matched allogeneic BM (“MiHA-mis”)
following reduced intensity conditioning (RIC). To examine the
involvement of CD80/CD86 expression in this resistance,
CD80 and CD86 mabs were administered to B6 (wt) BMT
recipients. Donor BALB.B BM was not rejected in these recip-
ients. To investigate the requirement of CD80/86 expression on
recipient cells with respect to development of resistance, BM
was transplanted into wt or B6-CD80-/-86-/- mice. Donor chi-
merism in both recipients was transient indicating resistance
had been elicited against the donor BM. CD80-/-86-/- BM was
then transplanted into “MiHA-mis” recipients following RIC.
In contrast to wt BM grafts, transplantation of CD80-/-86-/- BM
resulted in sustained donor chimerism. Since “MiHA-mis” BM
transplants into CD4-/- recipients demonstrated CD4 cell func-
tion is critical for resistance in this model, we hypothesized that
host CD4 cell recognition of donor APC results in the upregu-
lation of CD80/CD86 co-stimulatory molecules. WT and
CD40L-/- mice were transplanted with BALB.B BM and as
predicted, wt recipients rejected the donor BM. In contrast,
CD40L-/- recipients exhibited stable chimerism. To examine
the requirement of CD40L on CD4 cells in the host, CD4-/-
mice were transplanted with BM together with CD4 cells from
wt or CD40L-/- mice. Recipients co-transplanted with wt CD4
cells rejected their grafts whereas recipients of CD4 cells from
CD40L-/- donors expressed donor cell chimerism and failed to
resist the MHC-matched BM allograft. We interpret the ﬁnd-
ings to demonstrate a requirement for host CD4 cells to recog-
nize donor MiHA and undergo alloantigen induced activation
resulting in CD40L induction of CD80/86 on donor APC.
These interactions subsequently result in host CD8 cell effector
activity inhibiting donor engraftment. Since recipients contain-
ing anti-donor speciﬁc CD8 memory cells were found to resist
MHC-matched HCT containing CD80-/-86-/- APC, these ﬁnd-
ings support the notion that direct recognition of donor APC is
crucial to elicit T cell mediated resistance to hematopoietic
engraftment in naive RIC MHC-matched allogeneic recipients.
Ex vivo mab treatment of donor BM is being examined as a
potential translational application.
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LOW RATES OF CHIMERISM OCCUR WHEN ALEMTUZUMAB IS ADDED
TO CONDITIONING THERAPY FOR NON-MYELOABLATIVE ALLOGENEIC
STEM CELL TRANSPLANTATION
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Non-myeloablative allogeneic stem cell transplantation (NST)
aims to harness the graft-versus-tumor (GVT) effect while min-
imizing regimen-related toxicity, and relies on donor engraft-
ment to induce remission. The most appropriate GVHD pro-
phylaxis and preparative regimen in this setting remains poorly
deﬁned, though accumulating evidence suggests that full donor
chimerism is associated with maximal GVT effects and protec-
tion from relapse. Previously we found a high rate of donor
chimerism but a high incidence of severe GVHD using ﬂudara-
bine (ﬂu)/cyclophosphamide (Cy) conditioning and cyclospor-
ine (CSA)/mycophenolate moftil (MMF) as GVHD prophylaxis.
Subsequently, methotrexate (MTX) was substituted for MMF
and alemtuzumab (100 mg over 5 days, days -9 to -5) has been
added to our conditioning therapy in an attempt to both deplete
host antigen-presenting cells as well as infused donor T cells
and therefore minimize GVHD. Here we describe 55 patients
who received NST; 23 were conditioned with chemotherapy
alone and 33 were conditioned with alemtuzumab in addition to
ﬂu/Cy (n31) or ﬂu/melphalan (n2). All received CSA/MTX
post-transplant. The median age at NST was 50 years. Indica-
tions for transplant were Hodgkin’s disease (13), NHL (22),
MDS (7), CLL (5), myeloma (5) and 1 each with AML, breast
cancer, and and ovarian cancer. Most patients were heavily
pretreated and 62% had relapsed disease after prior autologous
SCT. There were no signiﬁcant differences between the groups
that did and did not receive alemtuzumab. Donor chimerism
was evaluated in all patients. 36% of patients conditioned with
alemtuzumabhad sustainable chimerism over 90%, and 42%
attained donor chimerism over 50%. This was signiﬁcantly
lower than in patients conditioned without alemtuzumab; 77%
and 82% had sustainable donor chimerism 90% and 50%
respectively (p0.005). There was no signiﬁcant difference in
median survival between patients treated with (12 mo) and
without (16 mo) alemtuzumab (p0.36). Relapse rates appeared
higher with alemtuzumab-containing regimens. Alemtuzumab
at this dose and schedule markedly decreased the incidence of
severe GVHD, but resulted in a higher incidence of graft-
rejection and hence lower rates of full and mixed donor chimer-
ism. Since full donor chimerism may be associated with freedom
from relapse, alternative conditioning regimens, and alternative
dosing and schedule of alemtuzumab administration (to deplete
host APC without in-vivo T cell depletion of the donor graft)
are being explored.
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TATION FOR PEDIATRIC PATIENTS WITH CHRONIC MYELOID LEUKE-
MIA
Kennedy-Nasser, A.A.1, Arce, J.1, Leung, K.S.1, Gottschalk, S.1,
Bollard, C.M.1, Heslop, H.E.1, Brenner, M.K.1, Krance, R.A.1 1Center
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Although allogeneic hematopoietic stem cell transplantation
(HSCT) from an HLA-matched sibling offers curative therapy
for the small numbers of children who develop chronic myeloid
leukemia (CML), less than one third of patients have an appro-
priately matched sibling. Alternative donor transplantation has
had a higher procedure-associated risk, particularly for graft-
versus-host disease (GVHD). We have attempted to reduce
these risks by incorporating alemtuzumab (Campath 1H) into
the preparative regimens for alternative donor grafts. Between
1996 and 2006, 19 pediatric CML patients were transplanted
using either matched sibling (MSD; n  9) or alternative donor
(AD; 5 matched unrelated; 2 mismatched unrelated; 3 mis-
matched related). All recipients of MSD grafts were in chronic
phase at the time of transplant as were 6 of the AD recipients;
three of the AD recipients were in accelerated phase and 1 in
chronic phase presenting in lymphoid blast crisis at the time of
transplant. All recipients received myeloablative conditioning
consisting of cyclophosphamide 45mg/kg x 2, cytarabine arabi-
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